切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2022, Vol. 11 ›› Issue (02) : 182 -187. doi: 10.3877/cma.j.issn.2095-3232.2022.02.014

临床研究

肝移植术后长期存活患者生存情况单中心分析
李嘉伟1, 庄雅峰1, 王明2, 柯瑞盛3, 江艺4, 蔡秋程4,()   
  1. 1. 350025 福州,福建医科大学福总临床医学院;350025 福州,解放军联勤保障部队第九〇〇医院肝胆外科
    2. 350025 福州,解放军联勤保障部队第九〇〇医院肝胆外科;350025 福州,厦门大学附属东方医院普通外科
    3. 361001 厦门,厦门大学附属第一医院普通外科
    4. 350025 福州,解放军联勤保障部队第九〇〇医院肝胆外科
  • 收稿日期:2021-12-01 出版日期:2022-04-10
  • 通信作者: 蔡秋程
  • 基金资助:
    福建省自然科学基金(2020Y0078); 福建省自然科学基金青年创新项目(2020J05299); 厦门市医疗卫生指导性课题项目(3502Z20209011)

Survival of long-term survivors after liver transplantation: a single-center analysis

Jiawei Li1, Yafeng Zhuang1, Ming Wang2, Ruisheng Ke3, Yi Jiang4, Qiucheng Cai4,()   

  1. 1. Clinical Medical College, Fuzhou General Hospital of Fujian Medical University, Fuzhou 350025, China; Department of Hepatobiliary Surgery, the 900th Hospital of Joint Logistics Support Force of Chinese PLA, Fuzhou 350025, China
    2. Department of Hepatobiliary Surgery, the 900th Hospital of Joint Logistics Support Force of Chinese PLA, Fuzhou 350025, China; Department of General Surgery, Dongfang Hospital Affiliated to Xiamen University, Fuzhou 350025, China
    3. Department of General Surgery, the First Affiliated Hospital of Xiamen University, Xiamen 361001, China
    4. Department of Hepatobiliary Surgery, the 900th Hospital of Joint Logistics Support Force of Chinese PLA, Fuzhou 350025, China
  • Received:2021-12-01 Published:2022-04-10
  • Corresponding author: Qiucheng Cai
引用本文:

李嘉伟, 庄雅峰, 王明, 柯瑞盛, 江艺, 蔡秋程. 肝移植术后长期存活患者生存情况单中心分析[J]. 中华肝脏外科手术学电子杂志, 2022, 11(02): 182-187.

Jiawei Li, Yafeng Zhuang, Ming Wang, Ruisheng Ke, Yi Jiang, Qiucheng Cai. Survival of long-term survivors after liver transplantation: a single-center analysis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2022, 11(02): 182-187.

目的

探讨肝移植术后长期存活(生存时间≥10年)患者生存情况。

方法

回顾性分析2005年1月至2010年12月解放军联勤保障部队第九○○医院行肝移植术后长期存活的104例患者临床资料。其中男91例,女13例;年龄15~71岁,中位年龄45岁。术前HBsAg阳性77例,阴性27例。患者均签署知情同意书,符合医学伦理学规定。观察患者肝移植术后胆道并发症、恶性肿瘤新发或复发、乙型病毒性肝炎(乙肝)新发或复发、感染、肾功能损害、代谢性并发症、心脑血管并发症、排斥反应等发生情况及死因。

结果

肝移植术后长期存活占同期手术患者的46.0%(104/226),其中原发性肝癌30例、胆管癌3例、肝衰竭64例、肝豆状核变性7例。随访时间120~191个月,中位随访时间142个月。随访期间胆道并发症10例,肿瘤复发5例、新发9例,乙肝复发6例、新发5例,肺部感染15例,结核感染5例,肾功能损害22例,高血压病34例,糖尿病31例,高脂血症29例,冠状动脉粥样硬化性心脏病7例,排斥反应18例。随访期间死亡6例,死于肺部感染3例,恶性肿瘤新发和(或)复发2例,慢性排斥反应1例。

结论

术后胆道并发症、恶性肿瘤及乙肝新发和复发、感染、肾功能损害、代谢性并发症、心脑血管并发症、排斥反应等对肝移植患者术后长期存活有重要影响,肺部感染、恶性肿瘤新发和复发是主要死因。

Objective

To investigate the long-term survival (survival time of ≥10 years) of the recipients after liver transplantation.

Methods

Clinical data of 104 patients who achieved long-term survival after liver transplantation in the 900th Hospital of Joint Logistics Support Force of Chinese PLA from January 2005 to December 2010 were retrospectively analyzed. Among them, 91 patients were male and 13 female,aged from 15 to 71 years, with a median age of 45 years. Prior to liver transplantation, 77 cases were positive and 27 cases were negative for HBsAg. The informed consents of all patients were obtained and the local ethical committee approval was received. The incidence of biliary complications, de novo or recurrent malignant tumors, de novo or recurrent hepatitis B virus infection (hepatitis B), infection, renal function damage, metabolic complications, cardio-cerebrovascular complications, rejections and causes of death after liver transplantation were observed.

Results

The long-term survival rate after liver transplantation was 46.0%(104/226), including 30 cases of primary liver cancer, 3 cases of cholangiocarcinoma, 64 cases of liver failure and 7 cases of hepatolenticular degeneration. Postoperative follow-up time was ranged from 120 to191 months, with a median of 142 months. During the postoperative follow-up, 10 cases of biliary complications, 5 recipients developed malignant tumor recurrence, 9 cases of de novo tumors, 6 cases of recurrent hepatitis B, 5 cases of de novo hepatitis B, 15 cases of pulmonary infection, 5 cases of tuberculosis infection, 22 cases of renal function damage, 34 cases of hypertension, 31 cases of diabetes mellitus, 29 cases of hyperlipidemia, 7 cases of coronary atherosclerotic heart disease and 18 cases of rejections. 6 recipients died during follow-up, including 3 cases of pulmonary infection, 2 cases of de novo and/or recurrent malignant tumors and 1 case of chronic rejection.

Conclusions

Postoperative biliary complications, de novo and recurrent of malignant tumors and hepatitis B, infection, renal function damage, metabolic complications, cardio-cerebrovascular complications, rejections exert significant effects upon the long-term survival of the recipients after liver transplantation. Pulmonary infection, de novo and recurrent malignant tumors are the major causes of death.

表1 104肝移植术后长期存活患者并发症情况
[1]
中华医学会器官移植学分会. 器官移植术后乙型肝炎病毒感染诊疗规范(2019版)[J/CD]. 实用器官移植电子杂志, 2020, 8(2):81-85.
[2]
中国医师协会器官移植医师分会,中华医学会器官移植学分会肝移植学组. 中国肝移植受者肾损伤管理专家共识(2017版)[J]. 中华消化外科杂志, 2017, 16(4):319-326.
[3]
李新宇,黄磊,朱继业, 等. 肝移植术后生存10年及以上患者远期并发症随访分析[J]. 中华全科医师杂志, 2019, 18(4):347-351.
[4]
吕少诚,潘冰,李立新, 等. 不同肝癌肝移植标准受者预后分析[J/CD]. 中华移植杂志(电子版), 2019, 13(3):206-209.
[5]
Umeshita K, Eguchi S, Egawa H, et al. Liver transplantation in Japan: registry by the Japanese Liver Transplantation Society[J]. Hepatol Res, 2019, 49(9):964-980.
[6]
王垒,范林,彭贵主, 等. 经胆囊管胆道引流在肝移植胆道并发症预防和治疗中的应用[J/CD]. 实用器官移植电子杂志, 2017, 5(1):52-55.
[7]
中华医学会器官移植学分会. 中国肝移植术后并发症诊疗规范(2019版)[J]. 器官移植, 2021, 12(2):129-133.
[8]
蔡云石,刘雄威,肖衡, 等. 肝移植术后胆道并发症的诊治[J/CD]. 中华肝脏外科手术学电子杂志, 2018, 7(5):391-395.
[9]
李名安,吴春,罗骏阳, 等. 经皮介入治疗在肝移植术后胆道并发症中的应用探讨[J]. 中华器官移植杂志, 2017, 38(3):165-171.
[10]
蔡秋程,杨芳,张小进, 等. 肝移植5年后生存影响因素分析[J]. 肝胆外科杂志, 2013, 21(3):174-176.
[11]
方程,严盛,郑树森. 肝移植术后胆道并发症的影响因素及诊治进展[J]. 中华普通外科杂志, 2014, 29(6):486-488.
[12]
Fujiki M, Hashimoto K, Palaios E, et al. Probability, management, and long-term outcomes of biliary complications after hepatic artery thrombosis in liver transplant recipients[J]. Surgery, 2017, 162(5):1101-1111.
[13]
Dumortier J, Chambon-Augoyard C, Guillaud O, et al. Anastomotic bilio-biliary stricture after adult liver transplantation: a retrospective study over 20 years in a single center[J]. Clin Res Hepatol Gastroenterol, 2020, 44(4):564-571.
[14]
李彦杰,马毅,郭志勇, 等. 肝癌肝移植术后复发和转移特点及预后因素分析[J]. 中国实用外科杂志, 2012, 32(8):655-658.
[15]
郑树森,程启阳,耿磊, 等. 肝癌肝移植术后肝癌复发研究新进展[J]. 中国普通外科杂志, 2019, 28(7):773-778.
[16]
Vivarelli M, Cucchetti A, La Barba G, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence[J]. Ann Surg, 2008, 248(5):857-862.
[17]
陈凯,王唑,史政荣. 肝移植术后肿瘤复发与免疫抑制剂的关系[J]. 中华肝胆外科杂志2021, 27(3):192-196.
[18]
刘少儒,许磊波. 肝癌肝移植术后复发转移的免疫治疗[J]. 器官移植, 2021, 12(3):272-279.
[19]
李照,朱继业. 免疫治疗时代下的肝癌肝移植[J]. 临床肝胆病杂志, 2021, 37(2):249-252.
[20]
Fung J, Wong T, Chok K, et al. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years[J]. Hepatology, 2017, 66(4):1036-1044.
[21]
Ueda Y, Marusawa H, Kaido T, et al. Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation[J]. Hepatol Res, 2013, 43(1):67-71.
[22]
Katz LH, Paul M, Guy DG, et al. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? systematic review and meta-analysis[J]. Transpl Infect Dis, 2010, 12(4):292-308.
[23]
中国医师协会器官移植医师分会,中华医学会器官移植学分会肝移植学组. 中国肝移植受者代谢病管理专家共识(2019版)[J]. 器官移植, 2020, 11(1):19-29.
[24]
中华医学会器官移植学分会. 中国移植后糖尿病诊疗技术规范(2019版)[J]. 器官移植, 2019, 10(1):1-9.
[25]
中华医学会器官移植学分会. 中国实体器官移植术后高血压诊疗规范(2019版)[J]. 器官移植, 2019, 10(2):112-121.
[26]
Aibara N, Ohyama K, Hidaka M, et al. Immune complexome analysis of antigens in circulating immune complexes from patients with acute cellular rejection after living donor liver transplantation[J]. Transpl Immunol, 2018(48):60-64.
[27]
中华医学会器官移植学分会. 中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)[J]. 器官移植, 2021, 12(1):8-14, 28.
[28]
Koo J, Wang HL. Acute, chronic, and humoral rejection: pathologic features under current immunosuppressive regimes[J]. Surg Pathol Clin, 2018, 11(2):431-452.
[1] 应康, 杨璨莹, 刘凤珍, 陈丽丽, 刘燕娜. 左心室心肌应变对无症状重度主动脉瓣狭窄患者的预后评估价值[J]. 中华医学超声杂志(电子版), 2023, 20(06): 581-587.
[2] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[3] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[4] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[5] 潘冰, 吕少诚, 赵昕, 李立新, 郎韧, 贺强. 淋巴结清扫数目对远端胆管癌胰十二指肠切除手术疗效的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 608-612.
[6] 张其坤, 商福超, 李琪, 栗光明, 王孟龙. 联合脾切除对肝癌合并门静脉高压症患者根治性切除术后的生存获益分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 613-618.
[7] 严庆, 刘颖, 邓斐文, 陈焕伟. 微血管侵犯对肝癌肝移植患者生存预后的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 624-629.
[8] 廖梅, 张红君, 金洁玚, 吕艳, 任杰. 床旁超声造影对肝移植术后早期肝动脉血栓的诊断价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 630-634.
[9] 张文华, 陶焠, 胡添松. 不同部位外生型肝癌临床病理特点及其对术后肝内复发和预后影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 651-655.
[10] 钟广俊, 刘春华, 朱万森, 徐晓雷, 王兆军. MRI联合不同扫描序列在胃癌术前分期诊断及化疗效果和预后的评估[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 378-382.
[11] 胡宝茹, 尚乃舰, 高迪. 中晚期肝细胞癌的DCE-MRI及DWI表现与免疫治疗预后的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 399-403.
[12] 陆萍, 邹健. 凝血和纤维蛋白溶解标志物的动态变化对急性胰腺炎患者预后的评估价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 427-432.
[13] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[14] 王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
[15] 索利斌, 刘鲲鹏, 姚兰, 张华, 魏越, 王军, 陈骏, 苗成利, 罗成华. 原发性腹膜后副神经节瘤切除术麻醉管理的特点和分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 771-776.
阅读次数
全文


摘要